Frederic Tangy PhD

Frederic Tangy is the inventor of the recombinant measles virus technology at the core of Oncovita’s therapeutic anticancer approach. With 30 years of expertise in virology and vaccinology, he is the author of over 150 research publications and the principal inventor of 25 international patents. He has headed two major research programs: the development of viral vaccines based on measles vaccine vector, and the systematic study of the interactions between the virus and host proteins using high-throughput functional genomic methods. Several of his research programs have led to industrial breakthroughs in the field of prophylactic and therapeutic vaccines in collaboration with GSK, Transgene, and Themis Bioscience. In addition to his primary research activity as head of the Viral Genomics and Vaccination Unit at Institut Pasteur, Frederic Tangy founded the International Vaccinology Course and was a member and VP of the Pasteur Scientific Council. As CSO, Frédéric Tangy will lead the translation of Oncovita’s candidates from the bench to the clinic.